Previous 10 | Next 10 |
2024-01-23 08:05:46 ET More on Lantheus Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation FDA accepts Lantheus's application for gener...
Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIR...
2024-01-21 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...
2024-01-20 09:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-11 09:56:01 ET More on Lantheus Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus says FY23 worldwide revenue is expe...
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes...
2024-01-09 08:47:19 ET More on Perspective Therapeutics Perspective Therapeutics to divest brachytherapy business Seeking Alpha’s Quant Rating on Perspective Therapeutics Historical earnings data for Perspective Therapeutics Financial information for P...
2024-01-09 08:02:28 ET More on Lantheus Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment William Blair downgrades Lantheus to market perform Lantheus, Point BioPharma drop amid results of SPLAS...
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Some...
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final ...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE ...
Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to...
2024-05-06 12:59:30 ET In this video, Motley Fool contributors Jason Hall and Tyler Crowe share two of their top stocks to buy in May, Realty Income (NYSE: O) , and Lantheus (NASDAQ: LNTH) . *Stock prices used were from the afternoon of May 1, 2024. The video was publi...